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ARTICLE
Clinical exome sequencing for cerebellar ataxia and
spastic paraplegia uncovers novel gene–disease
associations and unanticipated rare disorders
Bart P van de Warrenburg1, Meyke I Schouten2, Susanne T de Bot3, Sascha Vermeer3, Rowdy Meijer2,
Maartje Pennings2, Christian Gilissen2, Michel̀ AAP Willemsen1, Hans Scheffer2 and Erik-Jan Kamsteeg*,2
Cerebellar ataxia (CA) and hereditary spastic paraplegia (HSP) are two of the most prevalent motor disorders with extensive locus
and allelic heterogeneity. We implemented clinical exome sequencing, followed by ﬁltering data for a ‘movement disorders’ gene
panel, as a generic test to increase variant detection in 76 patients with these disorders. Segregation analysis or phenotypic re-
evaluation was utilized to substantiate ﬁndings. Disease-causing variants were identiﬁed in 9 of 28 CA patients, and 8 of 48
HSP patients. In addition, possibly disease-causing variants were identiﬁed in 1 and 8 of the remaining CA and HSP patients,
respectively. In 10 patients with CA, the total disease-causing or possibly disease-causing variants were detected in 8 different
genes, whereas 16 HSP patients had such variants in 12 different genes. In the majority of cases, the identiﬁed variants were
compatible with the patient phenotype. Interestingly, in some patients variants were identiﬁed in genes hitherto related to other
movement disorders, such as TH variants in two siblings with HSP. In addition, rare disorders were uncovered, for example, a
second case of HSP caused by a VCP variant. For some patients, exome sequencing results had implications for treatment,
exempliﬁed by the favorable L-DOPA treatment in a patient with HSP due to ATP13A2 variants (Parkinson type 9). Thus, clinical
exome sequencing in this cohort of CA and HSP patients suggests broadening of disease spectra, revealed novel gene–disease
associations, and uncovered unanticipated rare disorders. In addition, clinical exome sequencing results have shown their value
in guiding practical patient management.
European Journal of Human Genetics (2016) 24, 1460–1466; doi:10.1038/ejhg.2016.42; published online 11 May 2016
INTRODUCTION
Massive parallel sequencing is rapidly being applied to identify disease-
causing variants in disorders with locus and allelic heterogeneity. Both
targeted gene panel sequencing1 and exome or genome sequencing
approaches2–4 are being used in diagnostic neurogenetics. Both
approaches allow for parallel analyses of multiple genes (panels)
associated with a given disorder in a single test. However, where
targeted gene panel approaches are limited to this, exome (or genome)
sequencing enables variant detection beyond a predeﬁned gene panel
or in ‘broader’ gene panels. The unbiased nature of exome sequencing
can thus result in the discovery of novel gene–disease associations, in
the expansion of disease spectra, or in the recognition of very rare and
unanticipated disorders. On the other hand, exome sequencing bears
the risk of ﬁnding pathogenic variants in genes not related to the
original request. To minimize the chance of having such ‘unsolicited’
ﬁndings, bioinformatic gene panels may be used for initial ﬁltering.5
Here, we have used clinical exome sequencing with bioinformatic
gene panel ﬁltering for variant detection in cerebellar ataxia (CA) and
hereditary spastic paraplegia (HSP). The prevalence rates of CA and
HSP are 1–5 per 100 0006 and 1–10 per 100 000,7 respectively. CA
and HSP are genetically heterogeneous, with over 70 loci/genes
involved in each, often with little or no clues for genetic differentia-
tion. In this study, the exome sequencing data were managed using
a bioinformatic gene panel ﬁlter containing ∼ 200 genes for central
motor disorders, including not only CA and HSP, but also Parkinson’s
disease and various hyperkinetic movement disorders.
SUBJECTS AND METHODS
Patients
In total, 76 patients with CA (n=28) or HSP (n=48) were included for clinical
exome sequencing. The cohort was largely nonconsecutive. Patients with a
visiting history from our center were selected from corresponding databases,
contacted, and then referred to and counseled by a clinical geneticist. New
patients were recruited at their ﬁrst visit. No restrictions on age at onset or
inheritance pattern were made, but there had to be a clinical suspicion of a
genetic etiology, based on the combination of a CA and/or HSP phenotype plus
either an onset age below 45 years or a positive family history. The latter was
liberally deﬁned as any affected family member suggestive of dominant, recessive,
or X-linked inheritance. Moreover, mutations in the most likely gene(s) had to be
excluded. All patients were counseled by a clinical geneticist and informed
consent was obtained. From each family, only one patient (proband) was
included for exome sequencing. Candidate mutations were veriﬁed by Sanger
sequencing in affected family members whenever possible. All but three patients
were adults at the time of testing, but in many the disease had started in
childhood (see Tables 1 and 2). Most patients had already undergone extensive
genetic testing, with a mean of 4.5 genes for each group. Autosomal dominant
cerebellar ataxias caused by repeat expansions were excluded in all CA patients
with dominant or sporadic modes of inheritance. In addition, SPG types 4 and 7
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were excluded in ~75 and 50% of the HSP patients before exome sequencing.
The set of genes excluded per patient was quite variable, but this reﬂects the
variation of clinical practice in case of different requesting and referring
physicians. Clinical exome sequencing was approved by the Medical Review
Ethics Committee, Region Arnhem-Nijmegen, Number 2011/188.
Exome sequencing and data analysis
Exome sequencing was essentially performed as previously described.5 Brieﬂy,
capture of exons was done using an Agilent SureSelect Human All Exon 50 Mb
Kit (Santa Clara, CA, USA). Sequencing was performed using a Life
Technologies 5500XL machine (Thermo Fisher, Waltham, MA, USA) or an
Illumina Hiseq 2000 (San Diego, CA, USA). Read mapping and variant calling
were done using LifeScope Life Technologies (Thermo Fisher) for the 5500XL
data or BWA (mapping) and GATK (calling) for the Illumina data. A ﬁlter for a
‘movement disorders’ gene panel was applied. This panel consists of ∼ 200
genes implicated in various forms of CA, HSP, Parkinson’s disease, genetic
choreas, and other hyperkinetic movement disorders. Only genes with
substantial evidence (multiple families, functional evidence, and/or literature
reports) were included in this panel. Genes with repeat expansions as molecular
mechanism only were not included either. The genes in this panel and coverage
statistics are provided as Supplementary File 1) and can also be found at www.
genomediagnosticsnijmegen.nl/exome. Variants were prioritized based on the
following criteria: frequency (o5% dbSNP,o1% in-house database of45000
exomes), nucleotide and amino acid conservation (based on alignments),
relation of the gene to disease (per family), and inheritance pattern.5 All
reported variants were conﬁrmed by Sanger sequencing.
All possible causative variants have been deposited into the appropriate gene-
speciﬁc databases (https://grenada.lumc.nl/LOVD2/mendelian_genes (Patient
ID 0064817), PMM2 (Patient ID 0064818) or http://databases.lovd.nl/shared/
variants (SPG7), 00054866 (GOSR2), 00054867 (SCN8A), 00054869 (C10orf2),
00054870 (KCNC3), 00054871& 00054875 (OPA1), 00054872 (GBA2),
00054873 (FA2H), 00054874 (KIAA0196), 00054876 (TH), 00054877 and
00054878 (KIF1A), and 00054879 (LRRK2).
RESULTS
Diagnostic yield of exome sequencing for CA and HSP
Initially, variants were identiﬁed by exome sequencing and an in-
house designed ‘movement disorder’ ﬁlter in 33 of 76 patients. Some
of those were directly considered causative, whereas others needed
follow-up by segregation analysis, clinical re-evaluation, or biochem-
ical tests. Pathogenicity was based on nature of the variants and
previous reports (see Tables 1 and 2) and frequency in controls and
prediction algorithms (Table 3). Of the 28 CA patients, eventually 9
had causative variants, 1 a possibly causative variant, and another 4
likely noncausative variants (Table 4). Of the 48 HSP patients, 8 had
causative, 8 possibly causative, and 3 had likely noncausative variants.
Thus, the diagnostic yield of clinical exome sequencing in this cohort
is somewhere between 17 and 26 of 76 (∼1 in 4).
Molecular diagnoses in cerebellar ataxia
Three patients with autosomal recessive or sporadic CA had biallelic
SPG7 variants (Table 1a). Spastic paraplegia type 7 (SPG7) accounts
for 5–12% of autosomal recessive forms of HSP, depending on the
population tested.20 In approximately half of the SPG7 patients, CA is
an additional clinical feature.21 However, two of the three patients
described here had no pyramidal signs, but rather a pure CA; the third
did have pyramidal features at clinical re-evaluation. Two of these
patients are compound heterozygous for two common variants in
spastic paraplegia type 7, p.(Arg485_Glu487del) and p.(Ala510Val),
suggesting that pure ataxia caused by SPG7 variants is not caused by
speciﬁc variants, but part of the SPG7 disease spectrum.
Three other patients (4–6; Table 1a) had ataxia complicated by
seizures, and exome sequencing revealed variants in genes involved in
rare disorders. Patient 4 carried a de novo variant in SCN8A. Variants
in this gene are associated with early epileptic infantile encephalopathy
type 13.22 Patient 5 was homozygous for the only GOSR2 variant
known to date to cause progressive myoclonic epilepsy type 6,23
whereas patient 6 has an earlier described nonsense variant in
CACNA1A, a gene involved in various disorders with ataxia and/or
epilepsy.
The remainder of the variants (Table 1a) was considered to be
pathogenic in CA for several reasons. Patient 7 has ataxia complicated
Table 1 Cerebellar ataxia patients with (a) causative variants and (b) possible causative variants identiﬁed by exome sequencing
Patient Sex Onset Additional features Inherit. Gene Variant (DNA) (protein) Zygosity Disorder (inherit.)
(a)a
1 F 58 y None AR SPG7 c.1454_1462del; p.(Arg485_Glu487del)17
c.1529C4T; p.(Ala510Val)18
ch SPG7 (AR)
2 M 38 y None AR SPG7 c.1454_1462del; p.(Arg485_Glu487del)17
c.1529C4T; p.(Ala510Val)18
ch SPG7 (AR)
3b M 52 y Mild pyramidal signs LL S SPG7 c.1529C4T; p.(Ala510Val)18
c.1756G4T; p.(Glu586*)
ch SPG7 (AR)
4 M 6 mo ID, spasticity, epilepsy S SCN8A c.4351G4A; p.(Gly1451Ser)16 dn EIEE13 (AD)
5 F 2 y Myoclonus, dystonia, epilepsy, high CK AR GOSR2 c.430G4T; p.(Gly144Trp)c,9 ho EPM6 (AR)
6 F 12 y Epilepsy AD CACNA1A c.5569C4T; p.(Arg1857*)8 he EA2 (AD)
7 F o3 y Ovarian dysgenesis, deafness, neuropathy, ID AR C10orf2 c.1306G4C; p.(Gly436Arg)c ho MTDS7 (AR)
8 F o10 y Neuropathy AR PMM2 c.422G4A; p.(Arg141His)14
c.722G4C; p.(Cys241Ser)15
ch CDG1a (AR)
9b M 1 y Pyramidal signs LL S KCNC3 c.1268G4A; p.(Arg423His)10 he SCA13 (AD)
(b)d
10a F U Cataract, neuropathy U OPA1 c.965 T4G; p.(Met322Arg) he DOA+(AD, AR)
Abbreviations: F, female; M, male; LL, lower limbs; ID, intellectual disability; R, autosomal recessive; D, autosomal dominant; S, sporadic; U, unknown because of adoption; y, year; mo, month; ch,
compound heterozygous; dn, de novo; he, heterozygous; ho, homozygous.
Gene names are according to the HUGO Gene Nomenclature Committee (HGNC) and variant nomenclature is according to the Human Genome Variation Society (HGVS) guidelines.
aReference sequences used are: NM_003119.2 (SPG7); NM_014191.2 (SCN8A); NM_054022.2(GOSR2); NM_001127221.1 (CACNA1A); NM_021830.4 (C10Orf2); NM_000303.2 (PMM2); and
NM_004977.2 (KCNC3). OMIM disease IDs used are: 607259 (SPG7); 614558 (EIEE13); 614018 (EPM6); 108500 (EA2); 271245 (MTDS7); 212065 (CDG1a); and 605259 (SCA13).
bAffected family member(s) with same genotype.
cSame patient described before.5
dReference sequence used are: NM_130837.2 (OPA1). OMIM disease ID used: 125250 (DOA+).
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by ovarian dysgenesis, deafness, neuropathy, and a mild intellectual
disability that is compatible with mitochondrial DNA depletion
syndrome caused by C10orf2 (Twinkle) variants. In patient 8, two
well-characterized PMM2 variants with reduced enzymatic activity24
were identiﬁed. Despite the often severe CDG1a phenotype associated
with PMM2 variants, a relative mild neurological phenotype with
ataxia as the main feature has been described before.25,26 The missense
variant in KCNC3 (patient 9) was considered causative, as it has been
described earlier in ataxia and, in the present case, was found in an
affected sibling and in a mosaic state in the unaffected mother.
A heterozygous variant in OPA1, the gene for dominant optic
atrophy type 1 and optic atrophy-plus syndrome, was considered to be
possibly causative (patient 10, Table 1b). However, despite segregation
of this variant with the disease in two siblings and despite the fact that
this variant affects an evolutionary conserved residue, it is quite
uncertain whether this variant is the cause of the patient’s ataxia. The
optic atrophy plus syndrome is mostly a recessive disorder, and no
second variant was identiﬁed using this test. The test has several
limitations, including incomplete coverage of the gene, no detection of
deep-intronic variants (as have been found in OPA127), or the poor
detection of exon deletions/duplications. In addition, the OPA1 gene
seems to be quite a polymorphic gene, with many nonpathogenic
sequence variants. Analysis of the OPA1 gene from our anonymized
cohort of healthy parents from trio-based studies (n= 2224) revealed 7
infrequent (o1% carrier frequency) sequence variants that lead to
substitutions of moderately or well conserved amino acids. Thus,
further testing of the OPA1 gene and its involvement in this family’s
phenotype is warranted. Unfortunately, further segregation analysis
was not possible as the parents were not available for testing.
Other variants were thought to be possibly causative initially, but
eventually considered likely noncausative, for the following reasons:
(1) they did not segregate with the disease or (2) no second pathogenic
variant in the same gene was detected by Sanger sequencing in
recessive disorders (Supplementary File 2). Of note, AP5Z1
(KIAA0415) variants have been described in autosomal recessive
spastic paraplegia type 48.28 However, only two families have been
described in the original paper, and in a replication study no further
pathogenic AP5Z1 variants were identiﬁed in a cohort of 127 ataxia
patients.29 Two affected siblings from the original study were
homozygous for a frameshift variant, whereas a third unrelated patient
had only one heterozygous frameshift variant. These ﬁndings are
inconclusive concerning the putative inheritance pattern proposed for
AP5Z1 variants. The AP5Z1 nonsense variant in patient 28 was not
present in his affected sibling, making it an unlikely cause of the CA in
both siblings. Furthermore, using exome sequencing, we recently
identiﬁed another AP5Z1 heterozygous null variant (c.1312-2A4G)
that did not segregate with spastic ataxia in another family (not part of
this cohort), whereas a homozygous AP5Z1 nonsense variant was
revealed in a patient with retinitis pigmentosa but no motor
symptoms. Therefore, it seems unlikely that AP5Z1 variants are related
to disease and we consider SPG48 for now to be unconﬁrmed.
Molecular diagnoses in hereditary spastic paraplegia
In eight HSP patients, clinical exome sequencing revealed variants that
were considered causative because they had been described in other
Table 2 Hereditary spastic paraplegia patients with (a) causative variants and (b) possible causative variants identiﬁed by exome sequencing




11 M o20 y None AD RTN2 c.939del; p.(Thr314fs)b he SPG12 (AD)
12c M o3 mo None AD KIF5A c.611G4A; p.(Arg204Gln)b,11 he SPG10 (AD)
13c F 47 y None AD KIF5A c.396G4A; r.396_397ins247b he SPG10 (AD)
14 M 29 y Neuropathy AD KIF5A c.751G4A; p.(Glu251Lys)b,11 he SPG10 (AD)
15 M o3 y Ataxia, cataract, neuropathy, mild ID, thin corpus
callosum, white matter changes
AR GBA2 c.2233C4T; p.(Gln745*) ho SPG46 (AR)
16c M 4 y Ataxia, hypomimia AR FA2H c.554G4A; p.(Trp185*)
c.21del; p.(Ala8fs)d
ch SPG35 (AR)
17 M o1 y Parkinsonism, ID, slow vertical saccades U ATP13A2 c.2675G4A; p.(Gly892Asp)b ho PARK9 (AR)
18c F 15 y None AD KIAA0196 c.3103C4T; p.(Arg1035Cys)b he SPG8 (AD)
(b)e
19 M 6 y None S VCP c.278G4A; p.(Arg93His)b,f he IBMPFD (AD)
20c M 20 y None AR TH c.772G4A; p.(Glu258Lys) ho THD (AR)
21 F U None AD LRRK2 c.2500+5_ 2500+8del
r.2311_2500del/r.2345_2500del12
he PARK8 (AD)
22c M o3 mo None AD KIF1A c.221A4G; p.(Tyr74Cys) he SPG30 (AR)
23c M o20 y None AD KIF1A c.1894C4T; p.(Gln632*) he SPG30 (AR)
24 M 53 y None AD KIAA0196 c.247G4A; p.(Glu83Lys) he SPG8 (AD)
25 M o5 y Motor neuropathy, ID, mild ataxia S AFG3L2 c.2314C4T; p.(Leu772Phe) ho SPAX5 (AR)
26 M 20 y None AD OPA1 c.113_130del; p.(Arg38_Ser43del)13 he DOA+(AD, AR)
aReference sequences used are: NM_005619.3 (RTN2); NM_004984.2 (KIF5A); NM_020944.2 (GBA2); NM_024306.4 (FA2H); NM_022089.2 (ATP13A2); and NM_014846.3 (KIAA0196).
OMIM disease IDs used are: 604805 (SPG12); 604187 (SPG10); 614409 (SPG46); 612319 (SPG35); 606693 (PARK9); and 603563 (SPG8).5
bSame patient described before.5
cAffected family member(s) with same genotype.
dDetected after Sanger sequencing only.
eReference sequences used are: NM_007126.3 (VCP); NM_199292.2 (TH) NM_198578.3 (LRRK2); NM_001244008.1 (KIF1A); NM_014846.3 (KIAA0196); NM_006796.2 (AFG3L2); and
NM_130836.2 (OPA1). OMIM disease IDs used are: 167320 (IBMPFD); 605407 (tyrosine hydroxylase deﬁciency (THD)); 607060 (PARK8); 610357 (SPG30); 603563 (SPG8); 604581 (SPAX5);
and 125250 (DOA+).
fVariant from unaffected father, but IBMPFD shows reduced penetrance for most features.
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HSP patients before, they were null variants, or they segregated with
the disease (patients 11–18, Table 2a). Three of those were in KIF5A,
indicating that SPG10 is relatively frequent in this cohort of HSP
patients.
Surprisingly, one of the KIF5A variants (detected in patient 13
and her affected father) leads to intron retention in the mature
mRNA in lymphocytes (Supplementary File 3). This is predicted to
result in a premature termination codon. Despite the suggestion of
gain-of-function or dominant-negative effects of variants in SPG10,30
the variant spectrum consists of missense, splice site, and frameshift
variants, indicating that KIF5A haploinsufﬁciency may also be a
mechanism underlying SPG10.
Patient 11 has a heterozygous frameshift variant in RTN2. As two of
the three SPG12-causing variants in this gene described to date are
null variants,31 haploinsufﬁciency of RTN2 seems to cause SPG12.
Patient 15 has a homozygous nonsense variant in GBA2. This patient
has HSP complicated with a mild intellectual disability, cataract, and
neuropathy that are major characteristics of SPG46 caused by GBA2
variants.
Genetic and clinical follow-up of two other patients also conﬁrmed
the role of the identiﬁed variants in their spastic syndrome. In patient
16, one heterozygous FA2H variant was complemented with a second
variant identiﬁed by Sanger sequencing. The latter was missed by
exome sequencing because of coverage issues. The MRI in this patient
did not show iron accumulation, a variable ﬁnding in SPG35 due to
FA2H variants. ‘Reverse phenotyping’ was convincing for Kufor–
Rakeb syndrome in patient 17 with ATP13A2 variants, because of the
additional presence of mild Parkinsonism, upgaze limitation, and














AFG3L2 c.2314C4T p.(Leu772Phe) 0.0026 (Eu) 19 0 0.23 1.000 C0
ATP13A2 c.2675G4A p.(Gly892Asp) 0.00003 (Eu) 2 0 0.02 0.947 C0
C10orf2 c.1306G4C p.(Gly436Arg)5 Absent 0 0 0 1.000 C65
CACNA1A c.5569C4T p.(Arg1857*)8 Absent 0 0 — — —
FA2H c.554G4A p.(Trp185*) Absent 0 0 — — —
c.21del p.(Ala8fs) Absent 0 0 — — —
GBA2 c.2233C4T p.(Gln745*) Absent 0 0 — — —
GOSR2 c.430G4T p.(Gly144Trp)9 0.00007 (Eu) 5 0 0 1.000 C65
KCNC3 c.1268G4A p.(Arg423His)10 Absent 0 0 0 1.000 C25
KIAA0196 c.247G4A p.(Glu83Lys) Absent 0 0 0.03 0.982 C0
c.3103C4T p.(Arg1035Cys) Absent 0 0 0.01 0.751 C0
KIF1A c.221A4G p.(Tyr74Cys) Absent 0 0 0 0.999 C65
c.1894C4T p.(Gln632*) Absent 0 0 — — —
KIF5A c.611G4A p.(Arg204Gln) 11 Absent 0 0 0.03 1.000 C0
c.396G4A r.396_397ins2475 Absent 0 0 — — —
c.751G4A p.(Glu251Lys) 11 Absent 0 0 0 1.000 C55
LRRK2 c.2500+5_2500+8del r.2311_2500del/
r.2345_2500del12
0.0001 (EA) 1 0 — — —
OPA1 c.113_130del p.(Arg38_Ser43del)13 0.0022 (All) 20 1 — — —
c.965 T4G p.Met322Arg Absent 0 0 0.02 0.809 C0
PMM2 c.422G4A p.(Arg141His)14 0.011 (All) 50 0 0 0.510 C25
c.722G4C p.(Cys241Ser)15 0.00058 (Af) 9 0 0.04 0.982 C0
RTN2 c.939del p.(Thr314fs) 5 Absent 0 0 — — —
SCN8A c.4351G4A p.(Gly1451Ser)16 Absent 0 0 0 0.954 C0
SPG7 c.1454_1462del p.(Arg485_Glu487del)17 0.0015 (All) 6 6 — — —
c.1529C4T p.(Ala510Val)18 0.004 (All) 45 0 0 1.000 C65
c.1756G4T p.(Glu586*) Absent 0 0 — — —
TH c.772G4A p.(Glu258Lys)5 0.005 (SA) 46 1 0 0.669 C55
VCP c.278G4A p.(Arg93His)5 0.000015 (Eu) 1 0 0.12 0.991 C0
Abbreviations: EA, European American (from EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) May 2015); AA, African
American (from EVS); All, EA and AA (from EVS); Eu, European (from ExAC (Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) 11 May 2015); SA, South
Asian (from ExAC); Af, African (from ExAC).
Gene names are according to the HUGO Gene Nomenclature Committee (HGNC) and variant nomenclature is according to the Human Genome Variation Society (HGVS) guidelines.
Sorting intolerant from tolerant (SIFT) scores range from 0 to 1. The amino acid substitution is predicted damaging if the score is ≤0.05, and tolerated if the score is 40.05.19 PolyPhen-2
(Polymorphism Phenotyping v2) scores range from 0 to 1. The amino acid substitution is predicted benign if the score is ≤0.2, possibly damaging if the score is 0.2–0.85, or probably damaging if
the score is 40.85. Align GVGD provides a series of ordered grades ranging from the most likely deleterious ‘C65’ to the least likely deleterious ‘C0’, and has 7 grades: C65, C55, C45, C35, C25,
C15, and C0. Deleterious scores are in bold.












CA 9 1 4 14 28
HSP 8 8 3 29 48
Total 17 9 7 43 76
Numbers of CA or HSP patients are categorized according to ﬁndings in clinical exome sequencing
after gene panel analyses.
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cognitive decline (see Supplementary File 4). A pure HSP in patient 18
and her affected father is likely to be due to a KIAA0196 variant.
A relatively large group of HSP patients had variants of uncertain
pathogenicity (Table 2b). Variants in VCP can cause amyotrophic
lateral sclerosis type 14 (ALS14) and inclusion body myopathy with
early-onset Paget disease and frontotemporal dementia type 1
(IBMPFD1), a very heterogeneous disorder with reduced penetrance
of each feature. Recently, we reported on a VCP variant as a new cause
of HSP.32 The p.(Arg93His) variant in VCP in patient 19 is novel.
However, another variant of the same codon, p.(Arg93Cys), has been
described in IBMPFD1,33 suggesting that patient 19 is the second
case of HSP caused by a VCP variant. Similarly, patient 20 and his
sibling have HSP and a homozygous variant in TH that is normally
involved in autosomal recessive dopamine-responsive dystonia. The
p.(Glu258Lys) variant in TH in this family is likely to be causative, as
the same change, but of the adjacent and equally conserved codon
(p.(Glu259Lys)), has been described in patients with dopamine-
responsive dystonia.34 Unfortunately, a lumbar punction to study
dopamine metabolites and a trial with L-DOPA was refused by both
siblings. Interestingly, a variant in the GCH1 gene, causing autosomal
dominant dopamine-responsive dystonia, has recently been associated
with dopamine-responsive, autosomal dominant HSP,35 suggesting a
link between HSP and dystonia.
In the same group of possibly causative variants in HSP, several
variants in genes implicated in HSP (KIAA0196 and KIF1A) or in
other central motor disorders (LRRK2, AFG3L2, OPA1) were identi-
ﬁed, and some of the variants have been published before (but not in
HSP). Segregation analyses or functional studies were not possible to
conﬁrm or exclude the role of these variants in HSP because of various
reasons. However, an interesting observation is the ﬁnding of two
heterozygous KIF1A variants segregating in two families with auto-
somal dominant HSP. KIF1A variants have been associated with
autosomal recessive HSP in two families,36 and also in de novo
autosomal dominant intellectual disability with motor symptoms.37,38
All variants described in KIF1A in these conditions affect the kinesin
motor domain. The mechanism underlying these two different
disorders has not been established, but it is tempting to speculate
that the KIF1A variant that segregates with HSP in the family of
patient 22, which is also in its kinesin motor domain, may cause
autosomal dominant HSP. An apparent dominant inheritance of HSP
with normal cognition was recently suggested in one family.39
Interestingly, similar variants in the kinesin motor domain of the
KIF1A paralog KIF5A are involved in pure autosomal dominant
SPG10. The nonsense variant in patient 23, which is not in the kinesin
domain, is more difﬁcult to understand.
Three other variants identiﬁed in the cohort of HSP patients
(Supplementary File 5) were considered to be likely noncausative, as
they did not segregate with the disease (variant in KCNC3), were not
supported by biochemical analyses (GALC), or because no second
pathogenic variant in the same gene was identiﬁed (PNPLA6).
DISCUSSION
Clinical exome sequencing in CA and HSP has a high
diagnostic yield
Sequencing of single genes in monogenic disorders with high locus
and allelic heterogeneity, such as CA and HSP, has a low diagnostic
yield per gene. The most common dominant forms of CA are caused
by polyglutamine-coding repeat expansions. Spinocerebellar ataxia 3 is
the most prevalent CA in this group, accounting for 21% of all SCA
patients worldwide, though large differences between populations have
been reported.6 The most common recessive type is Friedreich ataxia,
with a prevalence of 2–4 in 100 000. As the total number of patients
with recessive CA is unknown, it is as yet unclear which fraction is
affected with Friedreich ataxia. The detection rate for other genotypes
declines steeply, with many forms being extremely rare with pre-
valences below 1%. Once the ataxias with repeat expansion have been
excluded, ∼ 70 other genes associated with various other forms of
ataxia remain candidates. Similarly, the most common form of HSP is
autosomal dominant (AD) SPG type 4,40 explaining ∼ 30 to 40% of
AD HSP. Many other HSP types are very rare, and sometimes have
been described in only one or a few families. The number of loci
involved in HSP has now exceeded 70. Thus, a generic test for parallel
analyses of all the nonrepeat CA and HSP genes is expected to have a
better overall yield than single gene tests. Considering the phenotypic
overlap between CA and HSP, a combined analysis of genes involved
in both groups of disorders is justiﬁed.41 Indeed, clinical exome
sequencing in this cohort showed a diagnostic yield (∼1 in 4),
comparable to earlier exome sequencing studies for CA.4 The reasons
for not detecting causative variants in approximately three-fourths of
the patients in the cohort may be heterogeneous, including that the
variants reside outside the tested regions (such as mitochondrial DNA,
introns, and promoters), that the variants are in ‘novel’ genes yet to be
identiﬁed as involved in a central motor disorder, that the variants are
not being picked up by this test (exonic regions that are not targeted,
poor coverage, or repeat expansions), or a nongenetic basis of the
disorder. In addition, it is worthwhile noting that this was a selection
of patients negative for conventional gene testing (4.5 genes on
average), decreasing the a priori chance to ﬁnd a variant by exome
sequencing. Of note, a limitation of our study was the lack of
systematicity in which genes were excluded before exome sequencing,
preventing making reliable frequency estimates.
However, our selection of cases for this testing strategy, that is, a
genetic etiology had to be suspected, might have led to a higher yield
than when a less selected cohort of CA and HSP patients would have
been tested. Future re-evaluation of the data (to detect variants in
newly identiﬁed genes) or future retesting (ie, genome sequencing or
mitochondrial DNA sequencing) may eventually provide a molecular
cause for some of the patients in the ‘unsolved’ group.
Of note, before exome sequencing was undertaken, repeat expan-
sion disorders were excluded in most CA patients (both here and the
study from Nemeth et al1), and similarly SPAST and SPG7 variants
were excluded in most of the HSP patients. As it is still not possible to
reliably detect repeat expansions by exome sequencing in CA, it
remains necessary to test for these ﬁrst. For HSP, however, clinical
exome sequencing could be the ﬁrst tier testing strategy that would
increase its diagnostic yield.
Uncertainty of the pathogenicity of a subset of variants
One of the challenges in clinical genetics is the determination of the
pathogenicity of a given variant. In part, variants are clearly or highly
likely to be pathogenic based on functional studies, segregation
analyses, frequencies of variants in patient and control sets, or simply
on the nature of the variant (such as nonsense variant in haploinsuf-
ﬁciency diseases). Others may seem pathogenic, but proof is lacking,
and their role in disease should be considered with great caution, and
this has been stressed for variants with uncertain pathogenicity in
ataxia by a discussion in the recent literature.42,43 Therefore, such
variants with uncertain pathogenicity (as in Tables 1b and 2b) should
be considered carefully and not be used in clinical decision making.
However, sharing these variants either in databases or via scientiﬁc
papers is key to build the publically available data allowing scrutiniza-
tion of the putative role of these variants in disease.
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Clinical exome sequencing reveals ‘old’ gene–‘new’ disease
associations
Clinical exome sequencing and ﬁltering for a broader panel of genes
involved in motor disorders has revealed some novel gene-to-disease
associations. SPG7 is the most common form of autosomal recessive
HSP and is in half of the cases associated with ataxia. Here, two
patients (1 and 2) with a pure ataxia were found to be compound
heterozygous for two common SPG7 gene variants. Similarly, other
exome sequencing studies had also revealed one patient with pure CA
due to SPG7 variants.4,44 Thus, the clinical spectrum of SPG7 variants
is expanded to pure CA. Similarly, a homozygous variant in the TH
gene in two siblings with HSP strongly suggests a role for this gene not
only in dopamine-responsive dystonia, but also in HSP. A third
observation is that of a dominant inheritance pattern of pure HSP in
two independent families with KIF1A variants that were until now
implicated in autosomal recessive HSP in two families or as de novo
variants in severe intellectual disability and a motor phenotype.37,38
For SPG7, this new association seems to be established with ﬁve
families (this and other reports). For TH and KIF1A, the identiﬁcation
of other families and/or functional studies are warranted to establish
their role in a wider disease spectrum.
Other observations in our cohort substantiate previously suggested
‘allelic’ disorders. These include the role of PMM2 not only in a severe
congenital disorder of glycosylation, but also in late-onset ataxia
(patient 8), a second VCP variant (patient 18) that likely explains HSP
and that suggest this form of HSP is allelic to ALS14 and IBMPFD1,
and a possible second case of autosomal recessive spastic-ataxia-
neuropathy syndrome (SPAX5)45 caused by variants in AFG3L2
(patient 24).
Some of our other ﬁndings cautiously hint toward other gene–
disease associations, but clearly require conﬁrmation by other cases or
functional tests. These are the possible role of LRRK2 (involved in
Parkinson’s disease) variants in HSP (patient 20), or that of OPA1
(the gene for dominant optic atrophy plus syndrome) in neurological
disorders without optic atrophy (patients 10 and 25).
Clinical exome sequencing uncovers unanticipated disorders
Other genetic disorders may escape from being recognized clinically,
simply because they are extremely rare, or because the disease may not
have progressed to the recognizable full-blown phenotype. For
example, patient 5 with myoclonic epilepsy type 6 due to GOSR2
variants had indeed gradually developed the classical phenotype of
ataxia with myoclonic epilepsy and other seizure types, although at age
13 there is still no scoliosis. Because of the locus heterogeneity in
ataxia–epilepsy syndromes and the rare occurrence of this rather new
type, myoclonic epilepsy type 6 was not considered clinically. Another
example in our cohort was that of Kufor–Rakeb syndrome (patient
17), who was initially diagnosed with a complex form of HSP because
spastic tetraplegia was predominant. Only after establishing a mole-
cular diagnosis, clinical re-examination (‘reverse phenotyping’)
conﬁrmed Kufor–Rakeb syndrome, leading to a favorable levodopa
trial. Moreover, this case illustrates that unexpected exome sequencing
ﬁndings can affect therapeutic management.
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